Finance

Beta
Lists
INO:NASDAQ
Inovio Pharmaceuticals Inc
$1.10
+1.85%
(+0.020) 1D
$1.09
-0.91% (-0.0100)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Open
$1.08
High
$1.12
Low
$1.08
Mkt. cap
90.50M
Avg. vol.
2.02M
Volume
1.19M
52-wk high
$2.98
52-wk low
$1.03
EPS
-$1.70
Beta
1.49
Shares outstanding
82.27M
No. of employees
112
Open
$1.08
High
$1.12
Low
$1.08
Mkt. cap
90.50M
Avg. vol.
2.02M
Volume
1.19M
52-wk high
$2.98
52-wk low
$1.03
EPS
-$1.70
Beta
1.49
Shares outstanding
82.27M
No. of employees
112
News stories
From sources across the web
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees112
Founded1999
Headquarters-
SectorBiotechnology
Websiteinovio.com
Analyst ratings
Based on 2 analysts giving stock ratings to INO in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current $1.10
$6.00 (+445.45%)
Average
$4.25 (+286.36%)
Lowest
$2.50 (+127.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Hold
Reiterated
$2.50
+127.3%
06/01/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$6.00
+445.5%
05/22/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
$13.00
+1,081.8%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
14.52M
13.33M
10.26M
14.07M
Cost of revenue
14.52M
13.33M
10.26M
14.07M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.56M
7.88M
7.22M
7.88M
Operating expense
8.56M
7.88M
7.22M
7.88M
Total operating expenses
23.08M
21.21M
17.48M
21.95M
Operating income
-23.08M
-21.21M
-17.48M
-21.95M
Other non operating income
-1.87M
-24.27M
21.17M
4.14M
EBT including unusual items
-23.52M
-45.50M
3.76M
-19.68M
EBT excluding unusual items
-23.57M
-45.52M
3.75M
-19.48M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-23.52M
-45.50M
3.76M
-19.68M
Net profit margin
-
-
-
-
Earnings per share
-0.61
-0.87
-0.28
-0.31
Interest and investment income
610.64K
552.11K
449.34K
439.59K
Interest expense
-
-
-
-
Net interest expenses
610.64K
552.11K
449.34K
439.59K
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.73M
-20.86M
-17.14M
-21.63M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of INO
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer